A Study of Weight Loss Medications in People With Endometrial Cancer Receiving Chemotherapy

Full Title

Pilot weight loss intervention with dual GIP/GLP-1 receptor agonist therapy in patients with endometrial cancer and obesity, overweight, with or without diabetes

Purpose

People with endometrial cancer often gain weight during and after chemotherapy. Medicines to reduce the risk of an allergic reaction for people receiving chemotherapy can also raise blood sugar. Weight gain can affect overall health and cancer recovery.

Weight loss medications such as tirzepatide and semaglutide work well in people without cancer. Researchers want to see if they can help manage weight and blood sugar in people receiving chemotherapy for endometrial cancer.

If you join this study, you will give yourself an injection of tirzepatide or semaglutide once a week. You will take the medication for up to 24 weeks.

Contact

For more information and to see if you can join this study, please call Dr. Angela Green’s office at 646-888-6792.